Annual report [Section 13 and 15(d), not S-K Item 405]

Organization, Consolidation and Presentation of Financial Statements

v3.25.1
Organization, Consolidation and Presentation of Financial Statements
12 Months Ended
Dec. 31, 2024
DESCRIPTION OF BUSINESS  
DESCRIPTION OF BUSINESS

NOTE 1 - DESCRIPTION OF BUSINESS

 

The business model of Zivo Bioscience, Inc. and its subsidiaries (Health Enhancement Corporation, HEPI Pharmaceuticals, Inc., Zivo Bioscience, LLC, Wellmetrix, LLC, WellMetris, LLC, Zivo Biologic, Inc., ZIVOLife, LLC, and Zivo Zoologic, Inc. (collectively the “Company”)) is to derive future income from licensing and selling natural bioactive ingredients derived from their proprietary algae cultures to animal, human and dietary supplement and medical food manufacturers.